Artichoke extracts: physiological effects, use in obstetric practice

Authors

DOI:

https://doi.org/10.18370/2309-4117.2018.40.80-86

Keywords:

artichoke extracts, physiological effects, obstetric practice

Abstract

The article has studied and analyzed numerous publications reflecting the results of studies on the physiological effects of artichoke extracts and the use of drugs on its basis in obstetric practice. The structural components of the artichoke are considered, the role of polyphenolic compounds, bioflavonoids, inulin, macro- and microelements in the biochemical processes of the organism is analyzed. Physiological effects of artichoke components were studied in detail. It is shown that they are not only antioxidant, but also hypocholesterolemic, membrane stabilizing, anti-inflammatory, antitumor, immunomodulating, etc.

Artichokes have a great preventive potential for increasing the elimination functions of the liver and kidneys, a high antioxidant resource. The multicomponent composition of artichoke extracts determines the versatile effect of the preparations synthesized on their basis. An important feature of artichoke preparations is safety of use, the possibility of using without age restrictions, as well as in children and during pregnancy. The only contraindication for the appointment of an extracts of artichoke is the obstruction of the biliary tract.

Particular attention is paid to the mechanisms of hepatoprotective and cholagogue effects of artichoke extracts. From the standpoint of evidence-based medicine, questions of the use of artichoke medications for gestosis, placental insufficiency, and conditions complicating the health of a pregnant woman are covered. In particular, the artichoke extract improves the state of chronic diseases of the gastrointestinal tract in pregnant women, reduces the severity of asthenic syndrome, improves fat metabolism, promotes the restoration of vitamin balance, protects the liver and kidneys from the effects of drugs used to relieve vomiting, increases the level of albumin, reduces bilirubin levels. In dermatosis of pregnant women, there is a decrease in cholestasis, elimination of itching. In jaundice in pregnant women artichoke extract provides hepatoprotective effect, reduces intrahepatic cholestasis, normalizes bilirubin levels in the blood.

Since many diseases in pregnancy are accompanied by activation of lipid peroxidation, changes in the structural properties of cell membranes, metabolic disorders, the use of artichoke extracts is completely justified. Detoxication, antioxidant, lipidormalizing and hepatoprotective properties of preparations based on artichoke extracts indicate the high feasibility of their use in obstetric practice.

Author Biography

О. В. Кравченко, Bukovinian State Medical University, Chernivtsi

MD, professor, head of the Department of Obstetrics, Gynecology and Perinatology

References

  1. Obstetrics: national guideline. Ed. by E.K. Ailamazyan, V.I. Kulakov, V.E. Radzinsky, G.M. Savelieva. Moscow. GEOTAR-Media (2013): 410, 659.
  2. Belyaeva, N.M., Tetova, V.B., Aleshkovich, T.V. “The use of hofitol in the complex therapy of viral hepatitis.” Russian gastroenterological journal 5 (2003): 11–12.
  3. Buranova, F.V.“Actual aspects of etiology, pathogenesis, diagnostics and treatment of placental insufficiency in pregnant women after extracorporeal fertilization.” Obstetrics and gynecology 6 (2011): 9–16.
  4. Gromova, O.A., Torshin, I.Y. “Hofitol is a standardized artichoke extract. Biochemical composition and pharmacological effects.” A difficult patient 4–5 (2009): 24–31.
  5. Zainalova, S.A. “Features of the morphofunctional state of the fetoplacental complex under adverse environmental factors.” Thesis for PhD degree, specialty 14.01.01 “Obstetrics and gynecology”. Astrakhan (2015): 85–90.
  6. Zakharova, I.N., Shishkina, S.V., Izzadust, F.N. “Treatment of dysfunctional disorders of the biliary tract in children.” Questions of modern pediatrics 2 (2005): 102–4.
  7. Stryuk, R.I., Travnikova, N.L., Pavlova, L.N., et al. “Clinical effectiveness of Hofitol in placental insufficiency in pregnant women with diseases of the cardiovascular system.” Practicing physician 5 (2004): 47–9.
  8. Kolomiytseva, A.G. “The use of the drug Hofitol in the treatment of fetoplacental insufficiency.” Gynecology 10 (2005): 39–41.
  9. Konev, Y.V., Zhuravleva, I.G., Trubnikova, I.A. “The use of hofitol in chronic diseases of the hepatobiliary system in the elderly.” Russian gastroenterological journal 2 (2004): 12–5.
  10. Lazebnik, L.B., Konev, Y.V., Zhuravleva, I.A. “A study of the efficacy and tolerability of hofitol in chronic diseases of the hepatobiliary system.” In: Results of the study of hofitol. Moscow (1999): 6–7.
  11. Logutova, L.S., Novikova S.V. “Application of hofitol for the prevention of placental insufficiency in pregnant women of high perinatal risk.” Russian bulletin of obstetrician-gynecologist 5 (2004): P. 43–7.
  12. Mamaeva, M.A. “Modern phytopreparations in the therapy of the combined pathology of the organs of the urinary system and the digestive tract.” Russian gastroenterological journal 4 (2000).
  13. Markin, S.S. “Clinical aspects, cholesterosis: pathogenesis.” Thesis abstract for MD degree. Moscow (1992).
  14. Melnik, T.N., Lipovenko, L.N. “Treatment of constipation in pregnant women.” Questions of gynecology, obstetrics and perinatology 2 (2003): 103–4.
  15. Minushkin, O.N., Zverkov, I.V. “About the clinical approbation of the drug hofitol.” In: Results of the study of hofitol. Moscow (1999): 36–42.
  16. Minushkin, O.N., Zverkov, I.V., Zhakova, I.I. “The use of Hofitol in the treatment of chronic hepatitis.” Clinical Herald 2 (1999): 57–9.
  17. Murashko, L.E., Burlev, V.A., Klimenchenko, N.I. “The use of hofitol in pregnancy.” Problems of pregnancy 1 (2000): 69.
  18. Patsaev, T.A., Mamedaliyeva, N.M., Ilyasova, N.T., et al. “The use of hofitol for the prevention of severe forms of gestosis.” Russian bulletin of the obstetrician-gynecologist 3 (2006): 52–7.
  19. Bashmakova, N.V., Sevostyanova, O.Y., Atayants, K.M., Shipitsina, E.A. The use of hofitol for the purpose of correction of lipid metabolism in women in the third trimester of pregnancy. Collection of the works of the Ural Research Institute for the Protection of Maternity and Infancy. Ekaterinburg (2006).
  20. Savelyeva, G.M. Obstetrics. Moscow (2010).
  21. Sidorova, I.S., Zarubenko, N.B., Gurina, O.I.“Modern tactics of treatment of patients with preeclampsia of varying severity.” Obstetrics and Gynecology 6 (2011): 42–6.
  22. Torshin, I.Y., Gromova, O.A. Expert analysis of data in molecular pharmacology. Moscow. MCNMO (2012): 349–82.
  23. Bellosta, S., Bogani, P., Canavesi, M., et al. “Mediterranean diet and cardioprotection: Wild artichoke inhibits metalloproteinase.” Mol Nutr Food Res 9 (2008).
  24. Buddington, K.K., Donahoo, J.B., Buddington, R.K. “Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers.” J Nutr 132.3 (2002): 472–7.
  25. Bundy, R., Walker, A.F., Middleton, R.W., et al. “Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis.” J Altern Complement Med 10.4 (2004): 667–9.
  26. Bundy, R., Walker, A.F., Middleton, R.W., et al. “Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial.” Phytomedicine 15.9 (2008): 668–75.
  27. Chloptsios, C., Karanasiou, V., Ilias, G., et al. “Cholecystitis during pregnancy. A case report and brief review of the literature.” Clin Exp Obstet Gynecol 34.4 (2007): 250–1.
  28. Dranik, L.I. “Polyphenol compounds of Artichoke. II.” Med Prom USSR 73 (1965): 13–5.
  29. Emendorfer, F., Emendorfer, F., Bellato, F., et al. “Antispasmodic activity of fractions and cynaropicrin from Cynara scolymus on guinea-pig ileum.” Biol Pharm Bull 28.5 (2005): 902–4.
  30. Emim, J.A., Oliveira, A.B., Lapa, A.J. “Pharmacological evaluation of the antiinflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice.” J Pharm Pharmacol 46.2 (1994): 118–22.
  31. Fang, J., Xia, C., Cao, Z., et al. “Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways.” FASEB J 19.3 (2005): 342–53.
  32. Ferracane, R., Pellegrini, N., Visconti, A., et al. “Effects of different cooking methods on antioxidant profile, antioxidant capacity, and physical characteristics of artichoke.” J Agric Food Chem 56.18 (2008): 8601–8.
  33. Gibson, G.R., Beatty, E.R., Wang, X., Cummings, J.H. “Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin.” Gastroenterology 108.4 (1995): 975–82.
  34. Gilat, T., Konikoff, F. “Pregnancy and the biliary tract.” Can J Gastroenterol 14 Suppl D (2000): 55–9.
  35. Grande, S., Bogani, P., de Saizieu, A., et al. “Vasomodulating potential of mediterranean wild plant extracts.” J Agric Food Chem 52.16 (2004): 5021–6.
  36. Griffaut, B., Debiton, E., Madelmont, J.C., et al. “Stressed Jerusalem artichoke tubers (Helianthus tuberosus L.) excrete a protein fraction with specific cytotoxicity on plant and animal tumour cell.” Biochim Biophys Acta 1770.9 (2007): 1324–30.
  37. Hammerl, H., Pichler, O. “Studies on the effects of an artichoke extract on the serum lipids with regard to the prophylaxis of arteriosclerosis.” Wien Med Wochenschr 109 (1959): 853–5.
  38. Hammerl, H., Pichler, O. “Possibility of causal treatment of bile duct diseases with an artichoke preparation.” Wien Med Wochenschr 107.25–26 (1957): 545–6.
  39. Hirano, T., Higa, S., Arimitsu, J., et al. “Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils.” Int Arch Allergy Immunol 134.2 (2004): 135–40.
  40. Hougee, S., Sanders, A., Faber, J., et al. “Decreased pro-inflammatory cytokine production by LPS- stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages.” Biochem Pharmacol 69.2 (2005): 241–8.
  41. Jimenez-Escrig, A., Dragsted, L.O., Daneshvar, B., et al. “In vitro antioxidant activities of edible artichoke (Cynara scolymus L.) and effect on biomarkers of antioxidants in rats.” J Agric Food Chem 51.18 (2003): 5540–5.
  42. Juzyszyn, Z., Czerny, B., Pawlik, A., Drozdzik, M. “Effect of artichoke extract (Cynara scolymus L.) on palmitic-1-14C acid oxidation in rats.” Mol Nutr Food Res 52.5 (2008): 589–94.
  43. Juzyszyn, Z., Czerny, B., Pawlik, A., Drozdzik, M. “The effect of artichoke (Cynara scolymus L.) extract on ROS generation in HUVEC cells.” Phytother Res 22.9 (2008): 1159–61.
  44. Kaur, N., Gupta, A.K. “Applications of inulin and oligofructose in health and nutrition.” J Biosci 27.7 (2002): 703–14.
  45. Kleessen, B., Schwarz, S., Boehm, A., et al. “Jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota of healthy volunteers.” Br J Nutr 98.3 (2007): 540–9.
  46. Miccadei, S., Di Venere, D., Cardinali, A., et al. “Antioxidative and apoptotic properties of polyphenolic extracts from edible part of artichoke (Cynara scolymus L.) on cultured rat hepatocytes and on human hepatoma cells.” Nutr Cancer 60.2 (2008): 276–83.
  47. Monforte, M.T., Trovato, A., Kirjavainen, S., et al. “Biological effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat.” Farmaco 50.9 (1995): 595–9.
  48. Nadova, S., Miadokova, E., Mucaji, P., et al. “Growth inhibitory effect of ethyl acetate-soluble fraction of Cynara cardunculus L. in leukemia cells involves cell cycle arrest, cytochrome c release and activation of caspases.” Phytother Res 22.2 (2008): 165–8.
  49. Ohta, A., Ohtuki, M., Takizawa, T., et al. “Effects of fructooligosaccharides on the absorption of magnesium and calcium by cecectomized rats.” Int J Vitam Nutr Res 64.4 (1994): 316–23.
  50. Ohtsuki, K., Abe, A., Mitsuzumi, H., et al. “Glucosyl hesperidin improves serum cholesterol composition and inhibits hypertrophy in vasculature.” J Nutr Sci Vitaminol (Tokyo) 49.6 (2003): 447–50.
  51. Panther, E., Blum, H.E. “Liver diseases in pregnancy.Dtsch Med Wochenschr.” 133.44 (2008): 2283–7.
  52. Peppercorn, M.A., Goldman, P. “Caffeic acid metabolism by gnotobiotic rats and their intestinal bacteria.” Proc Natl Acad Sci USA 69.6 (1972): 1413–5.
  53. Preziosi, P., Loscalzo, B. “Experimental evaluation of 1,4-dicaf- feiylquinic acid, the active principle of artichoke.” Arch Ital Sci Farmacol 7.4 (1957): 249–96.
  54. Roberfroid, M.B. “Inulin-type fructans: functional food ingredients.” J Nutr 137.11 (2007): 2493–502.
  55. Schutz, K., Muks, E., Carle, R., Schieber, A. “Quantitative determination of phenolic compounds in artichoke-based dietary supplements and pharmaceuticals by high-performance liquid chromatography.” J Agric Food Chem 54.23 (2006): 8812–7.
  56. Schutz, K., Persike, M., Carle, R., Schieber, A. “Characterization and quantification of anthocyanins in selected artichoke (Cynara scolymus L.) cultivars by HPLC- DAD-ESI-MSn.” Anal Bioanal Chem 384.7–8 (2006): 1511–7.
  57. Skarpanska-Stejnborn, A., Pilaczynska-Szczesniak, L., Basta, P., et al. “The influence of supplementation with artichoke (Cynara scolymus L.) extract on selected redox parameters in rowers.” Int J Sport Nutr Exerc Metab 18.3 (2008): 313–27.
  58. Thaysen, A.C., Bakes, W.E., Green, B.M. “On the nature of the carbohydrates found in the Jerusalem artichoke.” Biochem J 23.3 (1929): 444–55.
  59. Zhu, X., Zhang, H., Lo, R. “Phenolic compounds from the leaf extract of artichoke (Cynara scolymus L.) and their antimicrobial activities.” J Agric Food Chem 52.24 (2004): 7272–8.
  60. Zhu, X.F., Zhang, H.X., Lo, R. “Antifungal activity of Cynara scolymus L. extracts.” Fitoterapia 76.1 (2005): 108–11.

Downloads

Published

2018-04-30

How to Cite

Кравченко, О. В. (2018). Artichoke extracts: physiological effects, use in obstetric practice. REPRODUCTIVE ENDOCRINOLOGY, (40), 80–86. https://doi.org/10.18370/2309-4117.2018.40.80-86

Issue

No. 40 (2018)

Section

Drug therapy

License

Copyright (c) 2018 О. В. Кравченко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.